Influenza cases are rising globally, prompting concern among public health officials as a mutated strain of the H3N2 virus begins to undermine the effectiveness of current vaccines. the shift, first identified by researchers at Chulalongkorn University in Thailand, highlights the ever-evolving nature of influenza and the challenges in maintaining optimal vaccine coverage [[1]]. Despite last year seeing record high cases reported by the Thai Ministry of Public Health, experts emphasize that while the new strain is more transmissible, current antiviral treatments remain effective.
Flu Cases Surge as Strain Mutation Reduces Vaccine Effectiveness
A significant surge in influenza cases is currently underway, with a concerning shift in the dominant strain impacting vaccine efficacy. According to a recent post from Yong Poovorawan, a specialist in clinical virology at Chulalongkorn University’s Faculty of Medicine, the circulating influenza A H3N2 strain has undergone genetic changes.
These changes are substantially reducing the effectiveness of current influenza vaccines. This news comes as public health officials continue to emphasize the importance of preventative measures against respiratory illnesses. The current outbreak follows a period of high influenza activity, with last year seeing the highest number of cases recorded by the Thai Ministry of Public Health to date.
While the beginning of last year was marked by the A H1N1 2009 strain, the dominant strain shifted to influenza A H3N2 later in the year. Influenza B cases have been limited to the Victoria strain, with the Yamagata strain absent for the past five years, leading experts to suggest that a quadrivalent vaccine isn’t necessarily more effective than a trivalent one.
The H3N2 strain currently prevalent in the Northern Hemisphere during this winter season is particularly worrisome due to genetic alterations in the HA1 region of its immune system. These changes, approximately 6-9 points in number, allow the virus to evade existing vaccine-induced immunity. The strain has been designated as “K type” and is driving a significant increase in infections. The findings could influence future vaccine development and deployment strategies.
Despite the increased transmissibility resulting from these mutations, the severity of the illness hasn’t increased, and the effectiveness of antiviral medications remains unchanged. The primary impact of the strain is a larger number of cases due to the reduced vaccine protection.
Even with diminished vaccine effectiveness, health officials continue to recommend influenza vaccination. The currently available vaccines are inactivated, offering a high safety profile with minimal side effects and reasonable cost. This recommendation underscores the importance of maximizing available protection against the flu, even if it’s not a perfect match to the circulating strain.
Thailand is anticipating a new vaccine formulation from the Southern Hemisphere in March to better protect against the strain expected to circulate during the upcoming rainy season.
อ่านข่าวเพิ่มเติม
ติดตามเราได้ที่
